Categories AlphaGraphs, Earnings, Health Care

Earnings: Trxade Health (MEDS) reports 16% rise in FY22 revenue; loss narrows

Trxade Health, Inc. (NASDAQ: MEDS), a leading health service IT company, reported a double-digit increase in revenues for fiscal 2022. The company’s full-year net loss narrowed from the prior year.

Revenues increased 16% from last year to $11.45 million. As a result, the net loss attributable to Trxade Health narrowed to $3.47 million or $0.41 per share in fiscal 2022 from $5.32 million or $0.65 per share in the twelve months ended December 2021.

“I am pleased with the growth we have experienced in our Trxade platform. We continue to achieve key milestones in our internal roadmap with a focus on innovation and development through our various complementary growth opportunities,” said Trxade’s CEO Suren Ajjarapu.

Trxade’s stock has gained about 52% since the beginning of the year. The shares closed Monday’s regular trading session sharply higher.

Prior Performance

  • Trxade Q3 2022 earnings infographic
  • Trxade Q2 2022 earnings infographic
  • Trxade Q1 2022 earnings infographic
  • Trxade Q4 2021 earnings infographic

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

What to expect when Signet Jewelers (SIG) reports Q1 earnings

Shares of Signet Jewelers Limited (NYSE: SIG) were over 3% on Monday. The stock has dropped 13% over the past 3 months. The jewelry retailer is set to report its

MDB Infographic: Highlights of MongoDB’s Q1 2024 earnings report

Software company MongoDB, Inc. (NASDAQ: MDB) has announced financial results for the first quarter of 2024, posting an increase in revenues and adjusted profit. The company reported a 29% increase

Campbell Soup to report Q3 results Wednesday. Here’s what to expect

Campbell Soup Company (NYSE: CPB) is coming out of a rough patch after the packaged food company's sales and earnings got affected by the pandemic, due to the widespread movement

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top